Sunday 11 October 2026 Export all JNJ data to Excel Powerpack

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to June 2026, revenue grew 6.60%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

261.44 4.96 +1.93%

Follow JNJ

Alert me

Market cap: $618.1B
P/E: 30.3×
Fwd P/E: 24.9×
Dividend yield: 2.02%
F-score: 3/9
Altman Z: 4.78
Beneish M: −2.26
Dividend safety: 78/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Johnson & Johnson 10-K filed Feb 11, 2026

Fiscal year 2025 · Period ended Dec 28, 2025 · Filed Feb 11, 2026 · accepted 4:06 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1A, Risk Factors, against the 10-K filed Feb 13, 2025: 5 added · 10 modified; 7 with only figures updated

15 more changes in this Item, word by word, in Powerpack.